The brain is not exempt from peptide signaling — in fact, neuropeptides are among the most abundant and functionally diverse signaling molecules in the central nervous system. This has naturally led researchers to explore whether exogenous peptides might be able to modulate cognitive function, support neuroplasticity, or protect neurons from stress and damage. This article surveys some of the most studied cognitive peptides, with attention to both what the research shows and its significant limitations.
This content is strictly educational. None of the peptides discussed here are FDA-approved cognitive enhancers, and this article does not constitute medical advice.
Semax
Background
Semax is a synthetic heptapeptide (seven amino acids) based on the ACTH(4-7) fragment — a portion of adrenocorticotropic hormone that does not carry the adrenal-stimulating activity of full-length ACTH. It was developed in the Soviet Union and subsequently in Russia, where it received regulatory approval as a pharmaceutical drug (available as a nasal spray) for conditions including stroke recovery, cognitive decline, and ADHD-like presentations. Its regulatory status outside of Russia and Eastern Europe is not equivalent — it is a research compound in the United States, EU, and most Western countries.
Proposed Mechanisms
Semax has been studied for several mechanisms relevant to cognitive function:
- BDNF upregulation: Multiple preclinical studies have shown that Semax administration increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex — brain regions central to learning, memory formation, and executive function. BDNF is one of the most important proteins for synaptic plasticity, and its upregulation is a key target in cognitive enhancement research.
- NGF and VEGF expression: Animal studies suggest Semax may also upregulate nerve growth factor (NGF) and vascular endothelial growth factor (VEGF), supporting both neuronal survival and cerebrovascular health.
- Dopaminergic and serotonergic modulation: Research has suggested Semax may modulate monoamine neurotransmitter systems, which are centrally involved in attention, motivation, and mood regulation.
- Anti-inflammatory effects: Some studies indicate Semax may reduce neuroinflammation, which is increasingly recognized as a contributor to cognitive decline.
Human Research
Semax has more human research than most nootropic peptides, primarily from Russian clinical settings. Studies have examined its use in stroke recovery, optic nerve disease, and cognitive performance. A 2011 study published in Molecular Biology by Kolomin and colleagues examined transcriptional changes following Semax administration in healthy volunteers and in patients with cerebrovascular disease, documenting gene expression changes consistent with neuroprotective and neuroplastic mechanisms.
However, the majority of Semax human research comes from a single national research tradition with limited replication in Western clinical settings. Randomized controlled trial data meeting current methodological standards is sparse. The existing human evidence is intriguing but insufficient to support confident efficacy claims.
Selank
Background
Selank is a heptapeptide derived from the sequence of tuftsin (a naturally occurring immunomodulatory tetrapeptide) combined with an additional stabilizing sequence. Like Semax, it was developed in Russia and is approved there as a pharmaceutical for anxiety, asthenic conditions, and cognitive impairment. It too is a nasal spray formulation in Russian medicine. Outside Russia, it is a research compound.
Proposed Mechanisms and Research
Selank's research profile is distinct from Semax in its emphasis on anxiolytic (anti-anxiety) and mood-stabilizing properties alongside potential cognitive benefits. Research has proposed several mechanisms:
- GABA system modulation: Some evidence suggests Selank may enhance GABAergic activity, which could contribute to its anxiolytic effects in animal models.
- Enkephalin metabolism: Research by Semenova and colleagues, published in Bulletin of Experimental Biology and Medicine, suggested Selank may stabilize enkephalin metabolism — the body's endogenous opioid peptides that modulate pain, mood, and stress responses.
- Immune modulation: Given its tuftsin-derived sequence, Selank has shown immunomodulatory properties in animal studies, potentially reducing stress-induced immune dysregulation.
- BDNF effects: Like Semax, some studies have reported Selank-associated BDNF changes, though the data is less extensive.
The cognitive benefit hypothesis for Selank is partly indirect — the reasoning that reducing anxiety and improving stress resilience may allow cognitive performance to express more fully rather than directly enhancing cognitive mechanisms. This is biologically plausible but somewhat different from a direct nootropic mechanism.
Human clinical trial data for Selank follows the same pattern as Semax: limited, primarily from Russian sources, and not yet replicated in well-controlled Western trials.
Dihexa
Background and Mechanism
Dihexa (also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, or PNB-0408) is a small peptide derived from angiotensin IV, a fragment of the renin-angiotensin system. It was developed at Washington State University by Joseph Harding and colleagues. Research published in Journal of Pharmacology and Experimental Therapeutics suggested that Dihexa could potently stimulate synaptogenesis — the formation of new synaptic connections — in animal models, doing so at concentrations far lower than other compounds previously studied for this purpose.
The proposed mechanism involves the AT4 receptor (also called insulin-regulated aminopeptidase, IRAP) in the hippocampus, where Dihexa appears to act as an agonist. This receptor system has been implicated in memory consolidation and spatial learning.
Research Findings
The most cited Dihexa research comes from Washington State University studies examining memory performance in aged rat models. These studies reported that Dihexa significantly improved performance on memory tasks compared to controls, with effects exceeding those of brain-derived neurotrophic factor (BDNF) in some assays. The synaptogenic potency described in this research was striking enough to attract considerable attention in the research community.
However, Dihexa has several important caveats:
- Human clinical trial data is essentially absent. All efficacy evidence comes from animal models as of 2026.
- The compound is highly potent in animal assays, and the long-term consequences of chronic potent synaptogenesis are not well characterized — unregulated synapse formation could theoretically have unintended consequences.
- Independent replication of the WSU findings by other groups has been limited.
- The pharmacokinetics and safety profile in humans are not established.
Dihexa is perhaps the most preclinically interesting of the cognitive peptides reviewed here but also among those with the greatest gap between preclinical promise and established human evidence.
Other Cognitive Peptides of Note
Cerebrolysin
Cerebrolysin is a mixture of peptide fragments derived from pig brain tissue, used as an injectable pharmaceutical in Russia, China, and parts of Eastern Europe for stroke recovery and Alzheimer's disease. Unlike single-compound peptides, it is a complex mixture. Cochrane reviews and systematic analyses of its stroke and dementia trial data have found mixed results, with some individual trials suggesting benefits but meta-analyses arriving at inconclusive findings. It is not FDA-approved in the United States.
Dihexa vs. Semax vs. Selank: A Comparison
These three compounds occupy different positions in the evidence landscape:
- Semax and Selank have human use data (primarily from Russian clinical and pharmaceutical contexts) that, while limited by Western clinical trial standards, represents more direct human evidence than Dihexa.
- Dihexa has arguably the most striking preclinical findings but the least human evidence.
- All three lack the randomized controlled trial data from well-powered, pre-registered studies that would be needed to make confident claims about cognitive benefits in healthy humans.
The Challenge of Cognitive Enhancement Research
Studying cognitive enhancement presents unique methodological challenges beyond those in other therapeutic areas:
- Baseline effects: Compounds that reduce anxiety or improve sleep may appear to "enhance cognition" simply by removing cognitive impairments. Distinguishing true enhancement from impairment reversal requires careful baseline assessment and appropriate populations.
- Placebo effects in cognitive testing: Expectation strongly influences performance on cognitive tests, making blinding particularly important and difficult in this research area.
- Ecological validity: Performance on laboratory cognitive tasks may not translate to real-world cognitive function. Animal maze performance is even further removed from human cognitive outcomes.
- Neuroinflammation context: Many proposed cognitive peptides show stronger effects in models of neuroinflammation, injury, or aging. Their relevance to healthy young brains is less clear.
Medical Disclaimer
This article is provided for educational and informational purposes only. None of the peptides discussed — including Semax, Selank, Dihexa, or Cerebrolysin — are FDA-approved treatments for cognitive decline, dementia, ADHD, or any other cognitive or neurological condition in the United States. This content does not constitute medical advice, diagnosis, or treatment recommendations. Cognitive symptoms may indicate serious underlying medical conditions requiring professional evaluation. Anyone considering peptides or any other intervention for cognitive function should consult a qualified healthcare provider. The evidence base for cognitive peptides in healthy humans remains limited, and the long-term safety of many of these compounds in humans has not been established through controlled clinical trials.